Long-term quercetin supplementation reduces lipid peroxidation but does not improve performance in endurance runners

Shane D Scholten1
Igor N Sergeev2
1Department of Natural Sciences, University of Sioux Falls, Sioux Falls, SD, USA; 2Department of Health and Nutritional Sciences, South Dakota State University, Brookings, SD, USA

Purpose: To evaluate the effects of chronic quercetin supplementation on endurance performance and antioxidant status in long distance runners. We hypothesized that an improved antioxidant status can be associated with enhanced performance.

Methods: During 6 weeks of supplementation utilizing a double blind, randomized design, young male subjects received quercetin (1000 mg/day) or placebo while maintaining their current training schedules.

Results: Following the end of the supplementation period, there was a significant time × supplement interaction for serum malondialdehyde (MDA), an indicator of lipid peroxidation. There were no significant pre- to post-supplement changes in parameter values employed for measuring total antioxidant capacity, superoxide dismutase activity, and protein oxidation (protein carbonyl) in serum. There were also no significant pre- to post-supplement differences in VO2peak, running economy, heart rate, and rating of perceived exertion (RPE) during the 10 km time trial.

Conclusion: The findings obtained indicate that there is a relationship between quercetin supplementation and the statistically significant decreasing trend in MDA levels following 6 weeks of supplementation and training. This evidence suggests that quercetin can reduce oxidative stress (lipid peroxidation). However, performance improvements were not significant (as measured by VO2peak, running economy, heart rate, and RPE).

Keywords: quercetin, antioxidant capacity, oxygen consumption, running economy, exercise performance

Introduction

Quercetin, a flavonoid with high antioxidant activity, is abundant in many commonly consumed fruits and vegetables such as onions, berries, and apples. The typical US diet provides 5–40 mg/day of quercetin, but intake can reach 200–500 mg/day with high fruit and vegetable consumption.1 As a polyphenolic flavonoid, quercetin has been shown to be a powerful antioxidant. There is also evidence that quercetin can provide a number of health and performance benefits due to its antiviral, anti-inflammatory, anti-carcinogenic, cardioprotective, psychostimulating, and neuroprotective properties.2,3 In regards to physical performance, the potential for quercetin to be ergogenic lies in the electron donating capacity of its phenolic hydroxyl groups, reducing the effects of reactive oxygen species (ROS),4 and the possibility of increasing mitochondrial density.5 Few authors have studied quercetin’s effect on human performance, with consistent results being elusive.5–8 Reasons for equivocal findings include (1) acute supplement duration; (2) mode of exercise, with cycling having less muscle damage, inflammation, and oxidative stress than running; (3) quercetin cocktails with other...
isoflavones, catechins, vitamin C and E, and omega-3 fatty acids, not allowing for evaluation of the direct effects of quercetin benefits; and (4) dose/response variables have demonstrated many factors unique to individuals causing different absorption and storage capacities of quercetin.9

Oxidative stress during physical activity can cause damage to lipids, proteins, DNA, and carbohydrates if the increase in free radicals is greater than the ability to neutralize them. Byproducts of lipid and protein oxidation are malondialdehyde (MDA) and protein carbonyls, respectively. To measure the damage to cellular components by oxidation, studies have typically used MDA as a measure of oxidative stress induced by exercise.10

Most antioxidant supplementation studies on human performance have been carried out using vitamins A, C, and E. It has been suggested that antioxidant supplementation may improve performance by reducing oxidative stress to the contractile and structural proteins in muscle, thus limiting the inflammation and fatiguing effects of exercise.11,12 Contrary to this suggestion, vitamin C was found to delay the exercise recovery process and have no positive effect on the delayed onset muscle soreness.13

Human performance studies using antioxidant supplementation have been frequently carried out in a maximal exercise capacity such as a long duration race or via maximal oxygen testing. At exercise intensities over 80% VO2peak, antioxidant systems become overrun with ROS and no longer provide benefit.14 With extensive exercise durations, such as in long distance endurance runs, acute antioxidant supplementation may have no beneficial effect due to absent training effects and short half-life of the antioxidants used.

We found only two studies with a treatment time of at least 6 weeks where the effects of quercetin on endurance performance in humans have been evaluated. MacRae and Mefferd7 found a 3% improvement in cycle time trial performance following 6 weeks of supplementation. This performance improvement was not statistically significant but even a minor improvement for elite cyclists in competition can have a dramatic effect on final race results. It should also be noted that the placebo group in this study had a 1.5% performance improvement. The study by Bigelman et al15 found no significant difference in VO2peak or anaerobic performance measures with 6 weeks of quercetin supplementation in moderately trained military personnel. Neither of these two studies investigated the antioxidant effects of quercetin supplementation.

Several researchers have studied the acute effects of quercetin supplementation on performance measures.5,16–18 Because VO2peak and cellular adaptations take several weeks to improve with aerobic exercise training,19 it is likely that a similar duration of exercise with quercetin supplementation is warranted to produce significant performance improvements and develop an adaptation response to oxidative stress.

The purpose of this study was to compare the treatment effect of quercetin supplementation to placebo using trained, healthy, male endurance runners during a 6 week time period. To date, no other studies have investigated the antioxidant effects of quercetin in endurance performance over a training period longer than 7 days. First, we hypothesized that quercetin supplementation will result in less oxidative stress at baseline, after a VO2peak test and after a strenuous 10 km time trial (10 km TT) exercise bout as measured by lipid peroxidation (MDA) and protein oxidation (protein carbonyl) in serum. Second, we hypothesized that 6 weeks of quercetin supplementation and continued exercise training will increase endogenous antioxidant activity as measured by total antioxidant capacity (TAC) and superoxide dismutase (SOD) activity in serum. Lastly, we hypothesized an improved VO2peak, improved running economy, decreased heart rate, and rating of perceived exertion (RPE) during a 10 km TT for quercetin supplementation versus placebo.

Methods

Subjects

Eight males ages 18–39 volunteered to participate after a preliminary screening and explanation of all procedures and gave their written informed consent, according to the experimental procedures approved by the University of South Dakota, South Dakota State University, and University of Sioux Falls Institutional Review Boards. Subjects were recruited through the local running club and collegiate cross country teams. During the study, subjects were instructed to maintain their current training program and not alter the frequency, intensity, duration, or mode of exercise. Subjects were also instructed to maintain their dietary habits and refrain from any other supplementation.

All volunteers completed a medical history, exercise history, and Physical Activity Readiness Questionnaires at the first visit. All volunteers were required to be able to complete a 10 km run and have maintained an aerobic exercise program of at least 90–180 minutes per week at a 65%–85% maximum heart rate intensity for greater than 1 year. Subjects met the American College of Sports Medicine (ACSM) guidelines for apparently healthy individuals.20 Volunteers were excluded if they were currently supplementing with quercetin or other antioxidants, female, weighed less than 110 lbs, men under the age of 18 or over the age of 45, and had two or more of the fol-
lowing ACSM risk factors: family history, cigarette smoking, hypertension, dyslipidemia, impaired fasting glucose, obesity, or sedentary lifestyle. Subjects were required to abstain from vigorous activity for 48 hours prior to the second lab visit.

Subjects were randomly assigned in a double blind manner to a placebo or quercetin group. Treatment started after the completion of the first 10 km TT and continued for 6 weeks through completion of the second VO$_{2peak}$ and 10 km TT (Figure 1).

**Supplementation**

The quercetin supplement (Jarrow Formulas, Los Angeles, CA, USA) contained 500 mg of quercetin with no other antioxidants, which was confirmed by independent lab analysis (Novatia, Monmouth Junction, NJ, USA). The form of quercetin used was quercetin dihydrate which was found to dose dependently increase plasma concentrations in humans with 2 weeks supplementation.$^9$ Davis et al$^2$ found that after ingestion of a single dose of 250 mg or 500 mg quercetin, its peak concentration in the plasma is detected within 2–3 hours and the concentration returns to baseline in 24 hours. Subjects were instructed to take one pill in the morning and one pill in the evening for a total intake of 1000 mg/day. This intake amount was based on previous research regarding safety, bioavailability, and human plasma quercetin concentrations with supplementation.$^1$

**Experimental procedures**

At the second lab visit, baseline heart rate and blood pressure measurements were taken. Resting and exercise heart rates were measured using a wireless transmitter system (Polar Electro Inc, Woodbury, NY, USA). VO$_{2peak}$ was determined for all subjects using a previously published graded protocol$^{22}$ on a motorized treadmill (TrackMaster Model TMX325C, Full Vision, Newton, KS, USA) with expired gases analyzed using a Med Graphics CPX/D (St Paul, MN, USA) automated metabolic cart. After the VO$_{2peak}$ test, subjects were acclimated for the next session’s 10 km TT treadmill run which took place 24–48 hours after the VO$_{2peak}$ test.

During the 10 km TT, oxygen consumption, heart rate, and RPE values were recorded for one minute intervals at 3.2 km, 6.4 km, and 9.6 km. Subjects were instructed to complete the 10 km TT at their self-selected race pace. Run speed was recorded throughout the test. At the end of this study, the 10 km TT was repeated at the exact same run speeds and time as the preliminary 10 km TT to replicate the same intensity. Oxygen consumption, heart rate, and RPE values were again recorded at 3.2 km, 6.4 km, and 9.6 km and were used to measure the effects of supplementation.

Blood samples were drawn into tubes with no additives prior to the VO$_{2peak}$ test (Baseline), immediately post VO$_{2peak}$ (VO$_{2peak}$), and immediately post 10 km TT. Serum was obtained by centrifugation at 2000 g for 15 minutes. Aliquots of serum were immediately frozen at −80°C until analysis. Serum was analyzed for lipid peroxidation using OxiSelect MDA Adduct ELISA Kit (Cell Biolabs, Inc, San Diego, CA, USA), SOD activity using OxiSelect Superoxide Dismutase Activity Assay (Cell Biolabs, Inc), total antioxidant capacity using Total Antioxidant Capacity Assay Kit (BioVision, Mountain View, CA, USA), and protein carbonyl content was measured using OxiSelect Protein Carbonyl ELISA Kit (Cell Biolabs, Inc). All samples were run in duplicate.

**Statistical analysis**

The subjects were randomized into two groups: placebo ($n = 3$) and quercetin treatment ($n = 5$). Fifteen subjects were originally enrolled, however, during the normal training, three subjects acquired injuries not caused by the research design and four subjects did not meet the training requirements during the 6 week time frame. A three-way ANOVA with interactions was used to compare differences between variables. Significance for all comparisons was set at $P < 0.05$. This data analysis allowed group comparisons for individual assays and performance measures. All data were analyzed using R2.13.1 (http://www.r-project.org/).

**Results**

**Subject characteristics**

Descriptive information regarding subjects’ characteristics and VO$_{2peak}$ is presented in Table 1.
Performance

In response to the 6 week training and supplementation period, the \( \text{VO}_{2\text{peak}} \)(Table 2) increased by 11% and 6.1% in the quercetin and placebo groups, respectively. However, there were no significant interactions between pre-supplementation and post-supplementation with quercetin or placebo \( (P=0.172) \). The interactions were not significant for measures 3.2 km \( (P=0.967) \), 6.4 km \( (P=0.688) \), and 9.6 km \( (P=0.517) \).

Similar to \( \text{VO}_{2\text{peak}} \), heart rate response and RPE during the 10 km TT were not significantly different (Tables 3 and 4).

TAC

After 6 weeks of training there were no significant interactions between the predictive variables using TAC as the response (Table 5). When means between each of the individual predictive variables were explored, significant differences appeared between Baseline \( (3.20 \pm 0.03 \text{ nmol/mg protein}) \), \( \text{VO}_{2\text{peak}} \) \( (3.28 \pm 0.03 \text{ nmol/mg protein}) \), and 10 km TT \( (3.54 \pm 0.02 \text{ nmol/mg protein}) \), \( (P=0.007) \). Significant differences were also found between groups quercetin \( (3.20 \pm 0.06 \text{ nmol/mg protein}) \) and placebo \( (3.59 \pm 0.09 \text{ nmol/mg protein}) \), \( (P<0.001) \) when pre-supplementation was combined with post-supplementation. There were no significant differences between pre- and post-supplementation within groups quercetin and placebo \( (P=0.095) \).

Protein carbonyl

After 6 weeks of training, there were no significant interactions between the predictive variables using protein carbonyls as the response (Table 5). Significant differences appeared between Baseline \( (0.92 \pm 0.03 \text{ nmol/mg protein}) \), \( \text{VO}_{2\text{peak}} \) \( (0.95 \pm 0.01 \text{ nmol/mg protein}) \), and 10 km TT \( (0.98 \pm 0.02 \text{ nmol/mg protein}) \), \( (P=0.002) \). Significant differences also appeared between quercetin \( (0.93 \pm 0.01 \text{ nmol/mg protein}) \) and placebo \( (0.98 \pm 0.01 \text{ nmol/mg protein}) \), \( (P=0.005) \) when pre-supplementation was combined with post-supplementation. There were no significant differences between pre- and post-supplementation within groups quercetin and placebo \( (P=0.541) \).

MDA

After 6 weeks of training, there was a significant interaction between predictive variables using MDA as the response (Figures 2 and 3). The quercetin group decreased the amount of serum MDA by \( 0.69 \pm 0.22 \text{ pmol/mg protein} \) from pre-supplementation to post-supplementation, whereas the placebo group increased the amount of serum MDA by \( 0.88 \pm 0.53 \text{ pmol/mg protein} \) during the same time \( (P=0.019) \). However, no significant differences were found between Baseline \( (11.12 \pm 0.26 \text{ pmol/mg protein}) \), \( \text{VO}_{2\text{peak}} \) \( (11.12 \pm 0.26 \text{ pmol/mg protein}) \), and 10 km TT \( (10.73 \pm 0.35 \text{ pmol/mg protein}) \), \( (P=0.070) \) when individual predictive variables were explored. No significant differences were also found between quercetin \( (10.92 \pm 0.17 \text{ pmol/mg protein}) \) and placebo \( (11.38 \pm 0.38 \text{ pmol/mg protein}) \), \( (P=0.160) \) when pre-supplementation was combined with post-supplementation. There were no significant differences between pre- and post-supplementation within groups quercetin and placebo \( (P=0.753) \).

Table 1 Subject characteristics

<table>
<thead>
<tr>
<th>Group</th>
<th>Age (years)</th>
<th>Height (cm)</th>
<th>BW (kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quercetin</td>
<td>24.0 ± 5.4</td>
<td>175.3 ± 5.1</td>
<td>69.9 ± 9.5</td>
</tr>
<tr>
<td>Placebo</td>
<td>22.5 ± 3.0</td>
<td>171.5 ± 4.6</td>
<td>65.5 ± 3.9</td>
</tr>
</tbody>
</table>

Note: Values are means ± standard deviation.

Table 2 Peak oxygen consumption and rate of oxygen consumption for three distance points during a 10 km TT

<table>
<thead>
<tr>
<th>Group</th>
<th>Pre-supplementation</th>
<th>Post-supplementation</th>
<th>Two way interactions, P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>( \text{VO}_{2\text{peak}} )</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Quercetin</td>
<td>59.7 ± 3.6</td>
<td>66.6 ± 1.3</td>
<td>0.172</td>
</tr>
<tr>
<td>Placebo</td>
<td>59.0 ± 5.3</td>
<td>62.6 ± 5.9</td>
<td></td>
</tr>
<tr>
<td>3.2 km ( \text{VO}_{2} )</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Quercetin</td>
<td>50.0 ± 3.1</td>
<td>48.8 ± 5.2</td>
<td>0.967</td>
</tr>
<tr>
<td>Placebo</td>
<td>43.0 ± 2.6</td>
<td>41.9 ± 6.6</td>
<td></td>
</tr>
<tr>
<td>6.4 km ( \text{VO}_{2} )</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Quercetin</td>
<td>45.9 ± 3.6</td>
<td>48.9 ± 2.7</td>
<td>0.688</td>
</tr>
<tr>
<td>Placebo</td>
<td>45.3 ± 4.9</td>
<td>45.8 ± 4.4</td>
<td></td>
</tr>
<tr>
<td>9.6 km ( \text{VO}_{2} )</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Quercetin</td>
<td>47.1 ± 2.1</td>
<td>50.5 ± 1.7</td>
<td>0.517</td>
</tr>
<tr>
<td>Placebo</td>
<td>45.4 ± 10.2</td>
<td>50.2 ± 8.8</td>
<td></td>
</tr>
</tbody>
</table>

Notes: Values are means ± SD. Six weeks of supplementation between pre- and post-supplementation.

Abbreviations: 10 km TT, 10 km time trial; SD, standard deviation.
SOD

After 6 weeks of training there were no significant interactions between the predictive variables using protein carbonyls as the response (Table 5). Significant differences were found between Baseline (71.45 ± 3.21 U/mg protein), VO$_{2peak}$ (82.17 ± 4.69 U/mg protein), and 10 km TT (83.66 ± 3.63 U/mg protein), (P = 0.013). Significant differences also appeared between quercetin (72.89 ± 3.32 U/mg protein) and placebo (89.43 ± 2.60 U/mg protein), (P < 0.001) when pre-supplementation was combined with post-supplementation. There were no significant differences between pre- and post-supplementation within groups quercetin and placebo (P = 0.541).

All markers of oxidative stress and antioxidant activity are presented in Table 5. When using a three-way ANOVA with interactions, no significant differences were found.

Discussion

Our primary findings indicate that 6 weeks of dietary quercetin supplementation (1000 mg/day) did not significantly affect VO$_{2peak}$, heart rate, RPE, or oxygen consumption during the 10 km TT run. A recent meta-analysis found quercetin supplementation to have a statistical benefit in endurance performance but the effect is trivial to small. Our results demonstrate that there is a relationship between quercetin supplementation and the statistically significant decreasing trend in the serum MDA levels following 6 weeks of supplementation and training. These findings imply that quercetin reduced oxidative stress as measured by MDA, a product of lipid peroxidation. The reduction of oxidative stress can be a mechanism through which quercetin improves aerobic performance.

Davis et al found that endurance capacity with quercetin supplementation in mice was associated with positive changes in markers of mitochondrial biogenesis in just 7 days of supplementation. It is possible that flavanols, including quercetin, may enhance mitochondrial biogenesis in humans, hence improve aerobic performance. Flavonol rich lychee fruit extract, has been shown to decrease inflammation caused by high intensity exercise but, as in our study, did not significantly improve aerobic performance in humans.

Similarly, Nieman et al found that quercetin reduced inflammation but had no effect on cycling performance in trained cyclists.

In our study, quercetin supplementation did not enhance performance through peak oxygen consumption or running economy measured by oxygen consumption during

<table>
<thead>
<tr>
<th>Group</th>
<th>Pre-supplementation</th>
<th>Post-supplementation</th>
<th>Two way interactions, P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.2 km RPE</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Group Q</td>
<td>10.3 ± 0.6</td>
<td>12.0 ± 1.0</td>
<td>0.11</td>
</tr>
<tr>
<td>Group P</td>
<td>11.5 ± 0.3</td>
<td>10.3 ± 0.5</td>
<td></td>
</tr>
<tr>
<td>6.4 km RPE</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Group Q</td>
<td>14.5 ± 2.1</td>
<td>14.0 ± 1.4</td>
<td>0.39</td>
</tr>
<tr>
<td>Group P</td>
<td>12.7 ± 0.6</td>
<td>12.7 ± 0.6</td>
<td></td>
</tr>
<tr>
<td>9.6 km RPE</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Group Q</td>
<td>15.0 ± 2.0</td>
<td>14.7 ± 1.5</td>
<td>0.37</td>
</tr>
<tr>
<td>Group P</td>
<td>15.3 ± 2.5</td>
<td>15.0 ± 2.0</td>
<td></td>
</tr>
</tbody>
</table>

Notes: Values are means ± SD. Six weeks of supplementation between pre- and post-supplementation.
Abbreviations: 10 km TT, 10 km time trial; RPE, rating of perceived exertion; SD, standard deviation.

Table 4 RPE for three distance points during a 10 km TT

Table 3 Heart rate for three distance points during a 10 km TT

<table>
<thead>
<tr>
<th>Group</th>
<th>Pre-supplementation</th>
<th>Post-supplementation</th>
<th>Two way interactions, P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.2 km heart rate</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Group Q</td>
<td>169.4 ± 6.4</td>
<td>163.6 ± 2.6</td>
<td>0.08</td>
</tr>
<tr>
<td>Group P</td>
<td>170.3 ± 7.1</td>
<td>166.3 ± 4.0</td>
<td></td>
</tr>
<tr>
<td>6.4 km heart rate</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Group Q</td>
<td>173.2 ± 8.6</td>
<td>167.2 ± 6.4</td>
<td>0.19</td>
</tr>
<tr>
<td>Group P</td>
<td>175.6 ± 5.5</td>
<td>169.0 ± 2.6</td>
<td></td>
</tr>
<tr>
<td>9.6 km heart rate</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Group Q</td>
<td>175.2 ± 5.2</td>
<td>173.8 ± 9.8</td>
<td>0.07</td>
</tr>
<tr>
<td>Group P</td>
<td>191.4 ± 6.4</td>
<td>187.2 ± 4.2</td>
<td></td>
</tr>
</tbody>
</table>

Notes: Values are means ± SD. Six weeks of supplementation between pre- and post-supplementation.
Abbreviations: 10 km TT, 10 km time trial; SD, standard deviation.
a self-selected speed 10 km TT. The peak oxygen consumption results obtained are consistent with published studies on the ergogenic effect of quercetin supplementation in humans. Ganio et al24 found that 5 days of quercetin supplementation did not improve VO_{2\text{max}} in untrained, sedentary individuals. Cureton et al25 showed that 1000 mg/day of quercetin supplementation had no significant effect on VO_{2\text{peak}} or metabolic responses during submaximal cycling. Davis et al26 demonstrated that VO_{2\text{max}} improved by 3.9% with 7 days of quercetin supplementation (1000 mg/day) in untrained subjects.  

A significant difference between this study and ours is the conditioning of subjects with the subjects in the current study being well-trained versus untrained in the cited study. According to Vollaard et al,26 when assessing aerobic performance, it is important to utilize a direct measure of performance output to prevent the large individual variability outcome associated with a percentage of VO_{2\text{peak}}. Therefore, we analyzed differences in oxygen consumption at a self-selected 10 km TT pace from pre- to post-supplementation. A decrease in oxygen consumption indicates improved running economy, which can lead to an improved time trial performance or time to fatigue test. Consistent with the lack of changes in VO_{2\text{peak}}, we did not find that quercetin supplementation altered oxygen consumption at the self-selected 10 km TT pace.

It has been hypothesized that the antioxidant properties of quercetin may improve endurance performance by scavenging free radicals, and reducing systemic inflammation, damage to skeletal muscle's membranes and contractile proteins, and oxidative stress.27 Previous research by Hadley et al28 found an increase in urinary MDA excretion following exercise in the unsupplemented group and a decrease in urinary MDA following exercise in the supplemented (vitamins C and E) group. Similarly, we found no significant difference in serum MDA between quercetin and placebo before training. However, following training, the placebo group had an increase in serum MDA, while the quercetin group had a decrease in serum MDA, resulting in a significant interaction between the two groups with pre- and post-supplementation. This observation strongly supports our hypothesis of a decreased level of oxidative stress with quercetin supplementation. However, we did not observe any benefits in performance.

Unexpectedly, we found differences in TAC, protein carbonyl, and SOD activity between the quercetin and placebo groups. These differences were observed before and after supplementation, however, quercetin supplementation did not appear to have an effect. This may be due to subjects being randomized by VO_{2\text{peak}} rather than antioxidant or oxidative levels as well as a small sample size.

We found no changes in TAC, protein carbonyl, or SOD activity with 6 weeks of training and quercetin supplementation. These results are similar to the findings of Quindry et al,29 who found no alterations in post-race antioxidant capacity or oxidative damage with 3 weeks of quercetin supplementation prior to a 160 km endurance run, which took up to 30 hours to complete. In addition, there was no difference in performance between the supplemented and non-supplemented groups. Our findings are also similar to findings by McAnulty et al30 who supplemented trained cyclists for 3 weeks prior to a 3 day cycling bout of 57% of cyclist's VO_{2\text{max}} and demonstrated that although plasma quercetin increased, there were no changes in oxidative stress, inflammation, plasma antioxidant capacity, or performance.
The time of quercetin supplementation in our study (6 weeks) was much longer than in the study (9–16 days) by Cureton et al. Because VO$_{2\text{peak}}$ and cellular adaptations for mitochondrial biogenesis take several weeks to improve with aerobic exercise training, it is possible that, with a longer treatment time, we would find changes in performance measures. However, our findings imply that 6 weeks treatment time does not provide those adaptations. Contrary to our findings, Davis et al. found a significant improvement in VO$_{2\text{peak}}$ and endurance performance using human subjects during a cycling bout with quercetin supplementation for 7 days. The authors hypothesized that the change in performance was related to mitochondrial biogenesis, reduction of reactive oxygen species preventing fatigue, and/or the psychostimulatory effect, which may also delay fatigue. However, the biological mechanisms as to why the performance improved were not measured in this study.

It should be noted that although excessive oxidative stress can be detrimental to exercise performance, it is also known that blocking oxidative stress can hinder adaptations in the mitochondria, therefore stifling performance. Gomez-Cabrera et al. concluded that 8 weeks of antioxidant supplementation prevented cellular adaptations in untrained men who underwent strenuous indoor cycle training. Several researchers have used cocktails of antioxidant supplements in subjects involved in kayaking and downhill running and found an attenuation of ROS resulting in a delayed recovery of muscle function. Therefore, our null exercise performance findings may also be due to the potential negative effects of antioxidant supplements on performance.

Quercetin supplementation (1000 mg/day) has been shown to be safe and quercetin is currently a legal supplement. Further research is needed before a consensus statement can be made concerning its effectiveness. We found no performance benefits with 6 weeks of supplementation in long distance runners but did find a decrease in lipid peroxidation. The reduction of oxidative stress has been found to provide benefit to exercise performance, but has also been suggested to prevent adaptations from the stress of exercise.

Although we found a decrease in lipid peroxidation and no improvement in endurance performance, experimental limitations hamper simple interpretations of the results. Similarly to previous research by MacRae and Mefler, we restricted our sample to well-trained athletes where positive adaptations may be small and difficult to detect for those who have reached a ceiling for increasing muscle oxidative capacity due to high levels attained through training. To test for these potentially small adaptations, we used a 10 km TT to measure the VO$_{2\text{max}}$ heart rate, and RPE at specified intervals which can indicate changes in performance. Although this method doesn’t mimic a competitive event performance, it allowed us to control environmental factors that would normally affect race performances scheduled 6 weeks apart. There is also a
possibility that serum indicators of lipid peroxidation may not directly correlate with those indicators in muscle tissues that are responsible for exercise performance. Future studies are needed to examine the effect of quercetin with longer supplementation durations, greater bouts of intensity, greater sample size, and more specific measures of performance.

Conclusion
Quercetin has been found to improve athletic performance but the mechanisms involved are not yet clear. The results obtained in this study demonstrated, for the first time, that quercetin supplementation during training for 6 weeks can decrease oxidative stress in well-trained endurance athletes, implying the potential for improved endurance performance.

Acknowledgments
This work was funded in part by NIH Grant Number 2 P20 RR016479 from the INBRE Program of the National Center for Research Resources. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of NIH.

Disclosure
The authors report no conflicts of interest in this work.

References
7. MacRae HSH, Mefferd KM. Dietary antioxidant supplementation combined with quercetin improves cycling time trial performance. Int J Sport Nutr Exerc Metab. 2006;16(4):405–419.